Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., has promoted Kyle Jenne to chief commercial officer. This promotion is part of Akcea’s strategy to expand operations and to further invest in the TEGSEDI (inotersen) and WAYLIVRA (volanesorsen) launches globally, and new antisense assets to support the potential in-licensing of additional investigational therapies. “Kyle has the depth of experience necessary to help us build on our momentum as a global organi...